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Abstract: Gastric cancer is the fifth most common cancer worldwide with a poor survival rate.
Therefore, it is important to identify predictive and prognostic biomarkers of gastric cancer. Laminin
subunit beta 1 (LAMB1) is involved in attachment, migration, and organization during development,
and its elevated expression has been associated with several cancers. However, the role and mecha-
nism of LAMB1 in gastric cancer remains unknown. Here, we determined that LAMB1 is upregulated
in gastric cancer tissues and contributes to cell growth and motility. Using a public database, we
showed that LAMB1 expression was significantly upregulated in gastric cancer compared to normal
tissues. LAMB1 was also found to be associated with poor prognosis in patients with gastric cancer.
Overexpression of LAMB1 elevated cell proliferation, invasion, and migration; however, knockdown
of LAMB1 decreased these effects in gastric cancer cells. U0126, an extracellular signal-regulated
kinase (ERK) inhibitor, regulated the expression of LAMB1 in gastric cancer cells. Additionally, we
showed that c-Jun directly binds to the LAMB1 promoter as a transcription factor and regulates its
gene expression via the ERK pathway in gastric cancer cells. Therefore, our study indicates that
LAMB1 promotes cell growth and motility via the ERK/c-Jun axis and is a potential biomarker and
therapeutic target of gastric cancer.
Keywords: laminin subunit beta 1 (LAMB1); gastric cancer; cell proliferation; cell motility; ERK/c-
Jun/LAMB1 axis
1. Introduction
Gastric cancer is the most common contributor to the global burden of malignant tu-
mors and responsible for a high mortality rate worldwide [1,2]. Despite the advancements
in various cancer therapies, such as radiation therapy, immunotherapy, chemotherapy
and surgery, the five-year relative cancer survival rate remains poor with approximately
20% [3]. There is an urgent need to develop the diagnosis and new therapies for gastric
cancer, for which it is important to identify effective prognostic markers.
LAMB1, also known as Laminin β1, is composed of laminins and is present in most
of the tissues [4]. Generally, LAMB plays a role in initiating cell assembly by combining
with LAMC. Cell assembly plays an important role in cancerous cell invasion and metasta-
sis [5]. It has been reported that LAMB1 is highly expressed in several invasive cancers [6].
Laminin is a representative extracellular matrix (ECM) glycoprotein, which is composed of
large heterotrimeric protein complexes containing laminin subunit alpha, beta, and gamma
(also called LAMA, LAMB, and LAMC), and can assemble 16 isoforms of laminins in
humans [7]. Recently, laminin subunits, including LAMA, LAMB, and LAMC, have been
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shown to be involved in various cancer types affecting their oncogenic function, and thus,
were revealed as potential therapeutic target markers based on data analysis [8–11]. In
hepatocellular carcinoma (HCC), LAMB1 expression increases tumor progression during
invasion via PDGF/La axis-mediated LAMB1 translation [12]. LAMB1 levels are high in
the serum of colorectal cancer patients, so LAMB1 can be used as a potential serological
biomarker [13]. However, the function and mechanism of LAMB1 remain undefined in
gastric cancer. We hypothesized that LAMB1 might be involved in the oncogenic function
and cell motility of invasion and migration of gastric cancer cells. In this study, we aimed
to explore the effects of LAMB1 in gastric cancer.
The ERK pathway is a major trigger for the development of several cancers, including
lung, colorectal, breast, liver, and gastric cancer. In several studies, laminin has been shown
to be involved in the MAPK pathway, and MAPK/ERK signaling pathways regulate
LAMB1 expression in HCC [12,14]. c-Jun has been found to be a transcription factor
with oncogenic function in most cancers. The excessive expression of c-Jun plays an
important role in various biological functions, such as apoptosis, proliferation, invasion,
and migration [15–17]. It has been reported that the ERK pathway regulates c-Jun. c-
Jun-induced matrix metalloproteinase-1 (MMP1) expression-promoted cell motility [18].
Moreover, c-Jun, a transcription factor, regulates laminin 1 (also called laminin 111-alpha 1,
beta 1, and gamma 1)-induced cell growth [19]. We hypothesized that c-Jun is regulated
via the ERK pathway and regulates the transcription of laminin and laminin subunits.
In this study, we demonstrate that LAMB1 expression is elevated in gastric cancer
patients and that LAMB1 influences cell growth and motility in gastric cancer. Additionally,
we demonstrate that LAMB1 expression is regulated via the ERK pathway. In addition, the
transcription factor c-Jun can mediate LAMB1 transcription. Finally, we investigated the
mechanism of LAMB1 function and revealed that it could serve as a potential biomarker
and therapeutic target of gastric cancer.
2. Results
2.1. LAMB1 Is Upregulated in Gastric Cancer Patients in Public GEO Datasets
To identify the genes that are overexpressed in gastric cancer, we used the public
database of four gene expression omnibus (GEO) datasets (GSE2685, GSE13861, GSE33651,
and GSE63089) to analyze the differentially expressed genes (DEGs). Then, we searched
for genes upregulated in gastric cancer compared to normal tissues and classified them
in each public microarray dataset. The overall analysis pipeline is shown in Figure 1A.
The methods used and detailed information of the GEO datasets are described in Table 1.
GEO2R analysis using public GEO datasets generated Venn diagrams of 56 genes merging
the overexpressed genes in four GSE datasets of gastric cancer tissues (Figure 1B). To
identify the biological functions of these genes, we performed Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway and gene ontology (GO) analyses KEGG pathway
and GO annotation showed that the DEGs were most involved in various pathways, such
as extracellular matrix (ECM)-receptor interaction, ECM organization, cell adhension, and
structural constituents (Figure 1C and Figure S1). The data also showed that LAMB1
was involved in pathways, including ECM signaling and adhension, which mediated cell
motility and progression in cancer (Table 1, Table S1 and S2) [20]. Thus, we further explored
the role of LAMB1 in this study. In addition, to confirm the distribution of LAMB1 in GSE
datasets, we analyzed the relative gene expression. We showed that LAMB1 was located in
the middle position of the upregulated genes (Figure 1D). The information about genes
on the x-axis is described in Table S3. These results indicate that LAMB1 is upregulated in
gastric cancer based on the analysis of public GEO datasets.




Figure 1. Laminin subunit beta 1 (LAMB1) gene expression is upregulated in public datasets of gastric cancer patients. (A) 
Schematic presentation of the used gene expression omnibus (GEO) datasets. GEO series accession numbers were 
GSE2685, GSE13861, GSE33651, and GSE63089 . (B) Venn diagrams showing upregulated genes (logFC > 0.7, logFC > 0 
means overexpression in gastric cancer tissues) in gastric cancer tissues after applying GEO2R analysis. Numbers in red 
indicate merged genes in a public database of the four GSE datasets used for the analysis. (C) Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathway analysis of upregulated genes in a public database of GSE datasets used. The arrangement 
in order of low p-value is shown here. (D) Overall, the upregulated gene expression locus in gastric cancer tissue is pre-
sented. Red bar indicates LAMB1 locus. The x-axis showed the genes from GSE datasets. * p < 0.05; ** p < 0.01; *** p < 0.001, 
ns: not significant. 
Table 1. Relevant information retrieved from gastric cancer datasets of four GSE microarrays. 
GEO Accession Contributors, Year Country Platform Total Samples Cancer Tissue Normal Tissue 
GSE2685 Hippo, Y. et al. 2002 Japan GPL80 30 22 8 
GSE13861 Cho, J. et al. 2011 USA GPL6884 90 71 19 
GSE33651 Park, D. et al. 2011 South Korea GPL2895 52 40 12 
GSE63089 Zhang, X. et al. 2014 China GPL5175 90 45 45 
2.2. LAMB1 Is Significantly Upregulated and Correlated with Risk of Poor Prognosis in Gastric 
Cancer 
We reconfirmed the mRNA expression of LAMB1 using the publicly available GEO 
datasets of gastric cancer patients, which indicated significant overexpression of LAMB1 
in gastric cancer (Figure 2A). We also investigated LAMB1 expression in gastric cancer 
patient tissues. Examination of LAMB1 expression in six patients with normal and tumor 
tissues for gastric cancer showed an increase in the expression of LAMB1 in tumor than 
normal tissues (Figure 2B). Kaplan–Meier analysis showed that overexpression of LAMB1 
was associated with poor overall survival (OS), first progression (FP), and post-progres-
sion survival (PPS) of gastric cancer patients (Figures 2C and S2). These results suggest 
that overexpression of LAMB1 might be a potential indicator for poor prognosis in gastric 
cancer. 
i r . a inin subunit beta 1 (LAMB1) gene expression is upregulated in public datasets of gastric cancer patients.
(A) Schematic presentati n of the used g n expression omnibus (GEO) datasets. GEO series accession r
, , S 33651, and GSE63089. (B) Venn diagra s showing upregulated genes (logFC > 0.7, logFC >
0 means overexpression in gastric cancer tissues) in gastric cancer tissues after applying GEO2R analysis. Numbers in
red indicate merged genes in a public database of the four GSE datasets used for the analysis. (C) Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis of upregulated genes in a public database of GSE datasets used. The
arrangement in order of low p-value is shown here. (D) Overall, the upregulated gene expression locus in gastric cancer
tissue is presented. Red bar indicates LAMB1 locus. The x-axis showed the genes from GSE datasets. * p < 0.05; ** p < 0.01;
*** p < 0.001, ns: not significant.
Table 1. Relevant information retrieved from gastric cancer datasets of four GSE microarrays.
GEO Accession Contributors, Year Country Platform Total Samples Cancer Tissue Normal Tissue
GSE2685 Hippo, Y. et al., 2002 Japan GPL80 30 22 8
GSE13861 Cho, J. et al., 2011 USA GPL6884 90 71 19
S 33651 Park, D. et al., 2011 South Korea GPL2895 52 40 12
GSE63089 Zhang, X. et al., 2014 China GPL5175 90 45 45
2.2. LAMB1 Is Significantly Upregulated and Correlated with Risk of Poor Prognosis in
Gastric Cancer
We reconfi med th mRNA expression of LAMB1 using the publicly available GEO
d tasets of gastric cancer patients, which indicated significant overexpression of LAMB1
in gastric cancer (Figure 2A). We lso investigated LAMB1 expression in gastric cancer
patient tiss es. Examination of LAMB1 expression in six patients with normal and tumor
tissues for gastric cancer showed an increase in the expression of LAMB1 in tumor than
normal tissues (Figure 2B). Kaplan–Meier analysis showed that overexpression of LAMB1
was associated with poor overall survival (OS), first progression (FP), and post-progression
survival (PPS) of gastric cancer patients (Figure 2C and Figure S2). These results suggest
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that overexpression of LAMB1 might be a potential indicator for poor prognosis in gastric
cancer.




Figure 2. Overexpression of LAMB1 is correlated with an increased risk of gastric cancer. (A) Examination of LAMB1 gene 
expression in normal and gastric cancer tissues using a public database of GSE datasets. (B) Protein expression of LAMB1 
in six patients of gastric normal and tumor tissues using Western blot analysis. Relative expression of LAMB1 was ana-
lyzed by the ImageJ program. (C) Kaplan–Meier plots of the overall survival related to LAMB1 expression in a public 
database of gastric cancer patients. The data are presented as mean ±SEM. ** p < 0.01; *** p < 0.001, ns: not significant. 
2.3. LAMB1 Silencing Suppresses Proliferation, Invasion and Migration in Gastric Cancer Cells 
We confirmed LAMB1 expression in normal gastric cancer cells and six gastric cancer 
cell lines (Figure S3). Both mRNA and protein expression levels of LAMB1 we upregu-
lated in all gastric cancer cells, except in SNU-601 cells. To investigate the biological role 
of LAMB1 in gastric cancer, we generated AGS and MNN-28 cells for the knockdown of 
LAMB1 using designed siRNAs (Figure 3A). LAMB1 knockdown decreased cell prolifer-
ation in AGS and MNN-28 cells, which was confirmed using colony-formation assay but 
did not change the cell-cycle distribution (Figures 3B and S4). To determine whether 
LAMB1 expression influences cell motility during invasion and migration in gastric can-
cer, we showed that LAMB1 knockdown decreased cell invasion and migration in AGS 
and MKN-28 cells using Transwell assay (Figure 3C,D). These data indicate that LAMB1 
knockdown suppressed the biological role of proliferation, invasion, and migration in gas-
tric cancer cells. 
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by the ImageJ program. (C) Kaplan–Meier plots of the overall survival related to LAMB1 expression in a public database of
gastric cancer patients. The data are presented as mean ±SEM. ** p < 0.01; *** p < 0.001, ns: not significant.
2.3. LAMB1 Silencing Suppresses Proliferation, Invasion and Migration in Gastric Cancer Cells
We confirmed LAMB1 expressio in n rmal gastric ca cer cells and six gastric cancer
cell lines (Fi ure S3). Both mRNA and protein expression levels of LAMB1 we upregulated
in all gastric cancer cells, except in SNU-601 cells. To investigate the biological role of
L B1 in gastric cancer, we generated AGS and MNN-28 cells for the knockdown of
LAMB1 using designed siRNAs (Figure 3A). LAMB1 knockdown decreased cell prolifera-
tion in AGS and MNN-28 cells, which was confirmed using colony-formation assay but
did not change the cell-cycle distribution (Figure 3B and Figure S4). To determine whether
LAMB1 expression influences cell motility during invasion and migration in gastric cancer,
we showed that LAMB1 knockdown decreased cell invasion and migration in AGS and
MKN-28 cells using Transwell assay (Figure 3C,D). These data indicate that LAMB1 knock-
down suppressed the biological role of proliferation, invasion, and migration in gastric
cancer cells.




Figure 3. LAMB1 knockdown inhibits proliferation, invasion, and migration of AGS and MKN-28 cells. (A) mRNA and 
protein expression levels of LAMB1 in AGS and MKN-28 cells upon scrambled siRNA (scRNA) or LAMB1 siRNA#1, #2 
transfection. (B) Colony-formation assay showing cell proliferation of transfected AGS and MKN-28 cells upon LAMB1 
knockdown. (C) Cell invasion and (D) migration assays using transfected AGS and MKN-28 cells. Image magnification × 
200; scale bar, 50 μm. The data are presented as mean ± SEM (n = 3). ** p < 0.01; *** p < 0.001. 
2.4. LAMB1 Enhances Proliferation, Invasion and Migration in Gastric Cancer Cells 
LAMB1 overexpression in gastric cancer cells was examined in SNU-601 and SNU-
668 cells transfected with mock vector or LAMB1 overexpression vector (Figure 4A). The 
colony-formation assay using the transfected SNU-601 and SNU-668 cells showed an in-
crease in the number of colonies suggesting that LAMB1 overexpression induced cell pro-
liferation (Figure 4B). Moreover, LAMB1 overexpression significantly enhanced cell inva-
sion and migration in SNU-601 and SNU-668 cells, which was confirmed using Transwell 
assay (Figure 4C,D). These data suggest that LAMB1 overexpression induced cell prolif-
eration, invasion, and migration in gastric cancer cells. 
Figure 3. LAMB1 knockdown inhibits proliferation, invasion, and migration of AGS and MKN-28 cells. (A) mRNA and
protein expression levels of LAMB1 in AGS and MKN-28 cells upon scrambled siRNA (scRNA) or LAMB1 siRNA#1, #2
transfection. (B) Colony-formation assay showing cell proliferation of transfected AGS and MKN-28 cells upon LAMB1
knockdown. (C) Cell invasion and (D) migration assays using transfected AGS and MKN-28 cells. Image magnification ×
200; scale bar, 50 µm. The data are presented as mean ± SEM (n = 3). ** p < 0.01; *** p < 0.001.
2.4. LAMB1 Enhances Proliferation, Invasion and Migration in Gastric Cancer Cells
LAMB1 overexpression in gastric cancer cells was examined in SNU-601 and SNU-668
cells transfected with mock vector or LAMB1 overexpression vector (Figure 4A). The colony-
formation assay using the transfected SNU-601 and SNU-668 cells showed an increase in
the number of colonies suggesting that LAMB1 overexpression induced cell proliferation
(Figure 4B). Moreover, LAMB1 overexpression significantly enhanced cell invasion and
migration in SNU-601 and SNU-668 cells, which was confirmed using Transwell assay
(Figure 4C,D). These data suggest that LAMB1 overexpression induced cell proliferation,
invasion, and migration in gastric cancer cells.




Figure 4. LAMB1 overexpression promotes proliferation, invasion, and migration of SNU-601 and SNU-668 cells. (A) 
mRNA and protein expression levels of LAMB1 in SNU-601 and SNU-668 cells transfected with pCMV-3Tag-1A (Mock, 
empty vector) or pCMV-3Tag-1A-LAMB1 (pCMV-LAMB1, LAMB1 overexpression vector). (B) Colony-formation assay 
showing cell proliferation of transfected SNU-601 and SNU-668 cells with LAMB1 overexpression. (C) Cell invasion and 
(D) migration assays using transfected SNU-601 and SNU-668 cells. Image magnification × 200; scale bar, 50 μm. The data 
are presented as mean ± SEM (n = 3). ** p < 0.01; *** p < 0.001. 
2.5. U0126 Inhibits LAMB1 Expression in Gastric Cancer Cells 
In hepatocellular carcinoma (HCC), LAMB1 is known to upregulate cell signaling via 
the ERK and Akt pathways [12]. The ERK pathway is dominantly regulated by LAMB1 
expression in HCC. To identify the effect of the ERK pathway on LAMB1 expression in 
gastric cancer, we treated AGS and MKN-28 cells with the ERK pathway inhibitor, U0126. 
Western blot analysis of AGS and MKN-28 cells treated with U0126 for 24 h showed that 
the protein expression of LAMB1 was decreased upon U0126 treatment compared to 
DMSO treatment (Figure 5A). U0126 decreased the expression of LAMB1, thereby inhib-
iting its biological function of cell proliferation, invasion, and migration in gastric cancer 
(Figure 5B–D. We examined whether the rescue of LAMB1 expression can induce the pro-
liferation, invasion, and migration of cancer cells. We pretreated 10 μM U0126 for 24 h 
and then transfected with LAMB1 overexpression vector in AGS and MKN-28 cells ( 
Figure 5A). The recovery of LAMB1 expression in U0126-treated AGS and MKN-28 cells 
significantly increased cell proliferation, invasion, and migration (Figure 5B–D. These 
data indicate that LAMB1 expression is regulated via the ERK pathway and affects their 
biological function in gastric cancer. 
Figure 4. LAMB1 overexpression promotes proliferation, invasion, and migration of SNU-601 and SNU-668 cells. (A)
mRNA and protein expression levels of LAMB1 in SNU-601 and SNU-668 cells transfected with pCMV-3Tag-1A (Mock,
empty vector) or pCMV-3Tag-1A-LAMB1 (pCMV-LAMB1, LAMB1 overexpression vector). (B) Colony-formation assay
showing cell proliferation of transfected SNU-601 and S -668 cells with LAMB1 overexpression. (C) Cell invasion and (D)
migratio assays using transfected SNU-601 and SNU-668 cells. Image magnification × 200; scale bar, 50 µm. The data are
presented as mean ± SEM (n = 3). ** p < 0.01; *** p < 0.001.
2.5. U0126 Inhibits LAMB1 Expression in Gastric Cancer Cells
In hepatocellular carcinoma (HCC), LAMB1 is known to upregulate cell signaling via
the ERK and Akt pathways [12]. The ERK pathway is dominantly regulated by LAMB1
expression in HCC. To identify the effect of the ERK pathway on LAMB1 expression in
gastric cancer, we treated AGS and MKN-28 cells with the ERK pathway inhibitor, U0126.
Western blot analysis of AGS and MKN-28 cells treated with U0126 for 24 h showed
that the protei expression of LAMB1 was decreased upon U0126 treatment compared
to DMSO treatment (Figure 5A). U0126 decreased the expression f LAMB1, thereby
inhibiting its biological function of cell prolif ration, invasion, and migration in gastric
cancer (Figure 5B–D. We examined wheth the rescue of LAMB1 expression can induce
the proliferation, invasion, and migration of cancer cells. We pretreated 10 µM U0126 for
24 h and then transfected with LAMB1 overexpression vector in
(Figure 5A). The recovery of LAMB1 expression i U0126-treated AGS and MKN-28 c lls
significantly increased cell proliferation, inv sion, nd migration (Figure 5B–D). T se
data indicate that LAMB1 expression is regulated via the ERK pathway and affects their
biological function in gastric cancer.




Figure 5. Extracellular signal-regulated kinase (ERK) pathway inhibition reduces LAMB1 expression in AGS and MKN-
28 cells. (A) Protein expression level of LAMB1 in AGS and MKN-28 cells transfected with pCMV-3Tag-1A (Mock, empty 
vector) or pCMV-3Tag-1A-LAMB1 (pCMV-LAMB1, LAMB1 overexpression vector) after pretreatment with 10 μM U0126 
for 24 h. (B) Colony-formation assay showing cell proliferation of transfected AGS and MKN-28 cells with LAMB1 over-
expression after pretreatment with 10 μM U0126 for 24 h. (C) Cell invasion and (D) migration assays using transfected 
AGS and MKN-28 cells after pretreatment with 10 μM U0126 for 24 h. Image magnification × 200; scale bar, 50 μm. The 
data are presented as mean ±SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001. 
2.6. c-Jun Binds to LAMB1 Promoter Activate Transcription in Gastric Cancer Cells 
We screened the LAMB1 promoter to identify the transcription factor binding sites 
using PROMO 3.0. We found potential transcription factors that could bind to the proxi-
mal LAMB1 promoter, including c-Jun, C/EBPβ, RXRα, and YY1 (Figure 6A). To investi-
gate the effects of transcription factor-regulated mRNA levels of LAMB1, we generated 
AGS cells for knockdown using various siRNAs (Supplementary Figure S5A). This result 
showed that c-Jun knockdown effectively inhibited the mRNA expression of LAMB1 in 
AGS cells. Moreover, the c-Jun-binding motif is present in the LAMB1 promoter (<2000 
bp) region, and thus, we designed two potential binding sites (−1403 bp to −1225 bp and 
−1046 bp to −851 bp). ChIP assays showed that c-Jun directly binds to LAMB1 promoter 
in gastric cancer cells (Figure 6B). In the above results, U0126-treated gastric cancer cells 
exhibited decreased LAMB1 expression (Figure 5A). It has been reported that the expres-
sion of c-Jun is regulated via the ERK pathway in various cancers, including gastric cancer, 
mediating various cellular processes of cell growth, invasion, and migration [21]. We 
showed that U0126, an ERK inhibitor, decreased the protein expression of c-Jun and 
LAMB1, but reactivation of LAMB1 expression through the transfection of LAMB1 over-
expression vector in U0126-treated AGS and MKN-28 cells did not influence c-Jun expres-
sion (Figures 6C and S5B). Using the public GEO datasets, we showed a correlation be-
tween JUN (gene name of c-Jun) and LAMB1 gene expression (Figure 6D). Moreover, to 
determine whether knockdown of c-Jun inhibited the mRNA and protein expression of 
LAMB1 in gastric cancer, we treated AGS and MKN-28 cells with JUN-specific siRNAs 
Figure 5. Extracellular signal-regulated kinase (ERK) pathway inhibition reduces LAMB1 expression in AGS and MKN-28
cells. (A) Protein expression level of LAMB1 in AGS and MKN-28 cells transfected with pCMV-3Tag-1A (Mock, empty
vector) or pCMV-3Tag-1A-LAMB1 (pCMV-LAMB1, LAMB1 overexpression vector) after pretreatment with 10 µM U0126
for 24 h. (B) Colony-for ation assay showing cell proliferation of transfected AGS and MKN-28 cells with LAMB1
overexpression after pretreatment with 10 µM U0 26 for 24 h. (C) Cell invasion and (D) migration ass ys using transfected
AGS and MKN-28 cells after pretreatment with 10 µM U0126 for 24 h. Image magnification × 200; scale bar, 50 µm. The
data are presented as mean ± SEM (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001.
2.6. c-Jun Binds to LAMB1 Promoter Activate Transcription in Gastric Cancer Cells
We screened th LAMB1 promoter to identify the transcription factor binding sites
using PROMO 3.0. We found poten ial transcription factors that could bind to the p oximal
L MB1 promoter, including c-Jun, C/EBPβ, RXRα, and YY1 (Figure 6A). To investigate he
effects of tr nscription fact r-regula ed mRNA levels of LAMB1, w generated AGS cells
for knockdown using various siRNAs (Supplementary Figure S5A). This result showed
that c-Jun knockdown effectively inhibited the mRNA expr ssion of LAMB in AGS cells.
Moreover, the c-Jun-binding motif is pr sent in the LAMB1 promoter (<2000 bp) region,
a d thus, we designed two potential binding sites (−1403 bp to −1225 bp and −1046 bp
to −851 bp). ChIP assays showed that c-Jun directly binds to LAMB1 promoter in gastric
cancer cells (Figure 6B). In the above results, U0126-treated gastric cancer cells exhibited
decreased LAMB1 expression (Figure 5A). It has been reported that the expression of c-Jun
is regulated via the ERK pathway in various cancers, including gastric cancer, mediating
various cellular processes of cell growth, invasion, and migration [21]. We showed that
U0126, an ERK inhibitor, decreased the protein expression of c-Jun and LAMB1, but
reactivation of LAMB1 expression through the transfection of LAMB1 overexpression vector
in U0126-treated AGS and MKN-28 cells did not influence c-Jun expression (Figure 6C
and Figure S5B). Using the public GEO datasets, we showed a correlation between JUN
(gene name of c-Jun) and LAMB1 gene expression (Figure 6D). Moreover, to determine
whether knockdown of c-Jun inhibited the mRNA and protein expression of LAMB1 in
gastric cancer, we treated AGS and MKN-28 cells with JUN-specific siRNAs and found
that c-Jun knockdown decreased LAMB1 expression at both mRNA and protein levels in
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AGS and MKN-28 cells (Figure 6E). These results suggest that c-Jun directly binds to the
LAMB1 promoter and regulates the transcriptional gene expression of LAMB1 via the ERK
pathway in gastric cancer cells. Moreover, ERK/c-Jun/LAMB1 pathway may serve as a
novel therapeutic target in gastric cancer (Figure 7).
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Figure 7. Schematic model illustrating the role of LAMB1 in cell growth and motility through ERK/c-
Jun in gastric cancer. ERK/c-Jun axis elevates LAMB1 expression in gastric cancer. c-Jun directly
binds to the LAMB1 promoter and regulates the gene and protein expression levels of LAMB1.
Therefore, overexpressed LAMB1 promotes cell proliferation, invasion, and migration in gastric
cancer cells (red arrow).
Int. J. Mol. Sci. 2021, 22, 626 9 of 15
3. Discussion
Gastric cancer is an important contributor to the global burden of cancer for the past
several decades [22]. Diagnostic and surgical techniques have slightly improved the sur-
vival rate in gastric cancer patients. Although many potential biomarkers for gastric cancer
have been reported, limited therapeutic effects [23]. It is important to identify therapeutic
biomarkers of gastric cancer. Recently, it was reported that epithelial-mesenchymal transi-
tion (EMT) progression is required for the initiation of metastasis and tumor formation [24].
Extracellular matrix (ECM) components, such as laminin, are important regulators of EMT,
as well as tumor invasion and metastasis [20]. Extracellular matrix (ECM) is an important
component of the tumor microenvironment, which influences critical biochemical and
biomechanical effects of cancer development, progression, metastasis, and immune func-
tion [25,26]. The ECM has not only as of the scaffold upon but mediates critical biochemical
and biomechanical roles [25]. Upregulated or abnormally activated ECM proteins promote
cell proliferation, invasion, and migration in cancer [27]. The interactions between various
cell surface growth receptors and ECM components can influence the organization of
the cytoskeleton and intracellular signaling [26]. Thus, ECM components represent the
potential biomarkers for cancer diagnosis and prognosis.
Laminin activates various signal transduction pathways. Laminin involves tumor cell
attachment and proliferation laminin and induces invasion [28]. In metastatic cells, laminin
promotes activation of matrix metalloproteinase-2 (MMP2), which has a role in tumor cell
metastasis [29]. Recently, a study has reported that laminin chains have overexpression
and poor prognosis in various cancer patients [30–32]. LAMB1 gene was overexpressed in
several invasive cancers [6]. Reanalysis using GEO2R of in public GSE datasets showed
that the overexpressed genes, including LAMB1, are involved in pathways such as cell
adhesion and ECM interaction. We focused on LAMB1 as a potential biomarker and its
cellular mechanisms in gastric cancer. In this study, public datasets have demonstrated
that overexpression of LAMB1 in gastric cancer promotes tumor growth and is a marker of
poor prognosis. Knockdown of LAMB1 in vitro inhibited cancer cell growth and motility,
whereas overexpression of LAMB1 significantly enhanced cell proliferation, invasion, and
migration of gastric cancer cells. These results suggest that LAMB1 functions in tumor
growth and motility in gastric cancer.
The ECM-integrin receptor interaction activates the MAPK pathway [33,34]. The
MAPK pathway is essential for ECM determined cell survival. The MAPK/ERK signaling
pathway plays a crucial role in gastric cancer, such as tumorigenesis and progression [35].
Moreover, the ERK pathway regulates the invasion, migration, and metastasis progression
of malignant cancer. Interaction between laminin and cell surface receptors is an important
process in signal transduction pathways and is related to kinase-phosphatase cascade
stimuli gene expression and cellular function [36,37]. Recently, studies have reported
that the interaction between integrin and ECM promotes the intracellular pathway of
phosphorylated FAK and the ERK signaling in human gastric cancer cells [38]. LAMB1
expression is regulated via PDGF signaling, which activates the MAPK/ERK and PI3K/Akt
pathways in HCC, and the MAPK/ERK pathway efficiently mediates further activation
of LAMB1 express than PI3K/Akt pathway [12]. We used the inhibitor of U0126 (ERK
inhibitor) and LY294002 (Akt inhibitor). Similar to the above, LAMB1 was regulated on
gastric cancer cells through the ERK pathway compared to the Akt pathway. We found
that the ERK pathway regulates LAMB1 expression levels in gastric cancer, demonstrating
the regulation of LAMB1 via the ERK pathway, thereby inducing cancer cell growth and
motility. Inhibition of the ERK pathway is also a potential therapeutic target marker in
gastric cancer with LAMB1 overexpression.
We showed that LAMB1 is upregulated at both gene and protein expression levels
in gastric cancer tissues and cell lines. In HCC, the signaling pathway regulated LAMB1
translation during EMT, and cytoplasmic laminin affects the translation of LAMB1 in
cells [12]. However, little is known about the transcription factor or regulator of LAMB1 in
cancer. We focused on identifying a transcription factor regulating LAMB1 expression in
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gastric cancer. It has been reported that the transcription factor of the AP-1 complex binds
and regulates LAMB1 gene expression upon binding to its promoter in F9 mouse embryonal
cells and LAMC2 in HT29 human colon cancer cells [39,40]. AP-1 complexes are mediated
via the MAP kinase family, including ERKs and p38 [41]. c-Jun can promote the expression
of genes associated with ECM components and mediate cell growth and invasion in
cancer [18,42]. Additionally, c-Jun regulates the expression of laminin [19]. However, the
transcriptional role of c-Jun in regulating LAMB1 gene expression in gastric cancer has
not been studied yet. In this study, we observed a strong correlation between LAMB1 and
c-Jun gene expression. In addition, we found that c-Jun can bind LAMB1 promoter regions
and function as a transcription factor to regulate LAMB1 gene expression in gastric cancer,
which needs to be explored further to elucidate its function. The transcriptional activation
of LAMB1 by c-Jun in gastric cancer, which needs to be explored further.
In ECM remodeling in cancer, increased specific protein from ECM turnover is released
into the blood [43]. ECM proteins can be potentially used as a biomarker for early and
efficient detection. In early-stage of liver cancer, elevated LAMB1 mediated the increased
secretion of laminin 111 (Ln-111) [33]. The overexpressed laminin 111 interacts with its cell
membrane receptor, which further mediates cellular signaling, and promotes tumor growth
and metastasis. Although, we have shown the tissue LAMB1 expression is upregulated.
Moreover, we need to identify in the further study whether LAMB1 promotes the secretion
and expression of laminin 111 in gastric cancer. We believe that the overexpression of
LAMB1 may induce laminin overexpression, thereby mediating cancer progression and
metastasis, and can serve as a critical biomarker of gastric cancer.
4. Materials and Methods
4.1. Cell Lines and Patient Tissues
Human gastric cancer cell lines, including AGS, MKN-28, YCC-2, SNU-216, SNU-
601, and SNU-668, were purchased from the Korean Cell Line Bank (Laboratory of Cell
Biology, Cancer Research Center and Cancer Research Institute, Seoul National University
College of Medicine, Seoul, Korea). Human normal gastric epithelial cell line (GES-1) was
obtained from Yonsei Cancer Center (Seoul, Korea). All cells were cultured in RPMI-1640
medium (Welgene, Gyeongsan-si, Korea) containing 5% fetal bovine serum (Corning Costar,
Corning, NY, USA) and 1% antibiotic-antimycotic (Gibco, Waltham, MA, USA) in a 37 ◦C
incubator supplied with 5% atmospheric CO2. Two pairs of 2-mm-sized biopsy specimens
were obtained from 52 patients with gastric adenocarcinoma during diagnostic endoscopic
submucosal dissection. Immediately after biopsy, these tissue samples were frozen in liquid
nitrogen in a deep-freezer at −70 ◦C until further use. All participants provided written
informed consent. All experimental procedures were approved by the Institutional Review
Board of the National Cancer Center (approval number, NCCNCS-09-215; approval data,
02/26/2009).
4.2. Plasmid Infection and Transient Transfection
LAMB1 cDNA clones were provided by the Korea Human Gene Bank (KHGB). The
human LAMB1 construct was cloned into the pCMV-3Tag-1A plasmid in BamH1/Xho1
restriction enzyme sites to generate pCMV-LAMB1. Primer sequences for LAMB1 with
BamH1/Xho1 enzyme site are 5′-AATACGGATCCATGGGGCTTCAGTTGCT-3′ (forward,
with BamH1) and 5′-ACGAGCTCGAGTTACAAGCATGTGCTATACA-3′ (reverse, with
Xho1). The sequences of human siRNAs purchased from Genolution Inc (Genolution,
Seoul, Korea)., and siRNA sequences used in this study are as follows: LAMB1_siRNA#1, 5′-
GAGAUAACCUUCUGGAUUCUU-3′ (forward) and 5′-GAAUCCAGAAGGUUAUUAUCUCUU-
3′ (reverse); LAMB1_siRNA#2, 5′-GGAUUUCUACCAUGAUUUAUU-3′ (forward) and 5′-
UAAAUCAUGGUAGAUUUAUU-3′ (reverse); c-Jun_siRNA#1, 5′-GAGCUGGAGCGCCUG
AUAAUU-3′ (forward) and 5′-UUAUCAGGCGCUCCAGCUCUU-3′ (reverse); c-Jun_siRNA#2,
5′-GAGCGGACCUUAUGGCUACUU-3′ (forward) and 5′-GUAGCCAUAAGGUCCGCUCUU-
3′ (reverse); C/EBPβ_siRNA, 5′-CCAAGAAGACCGUGGACAAUU-3′ (forward) and 5′-
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UACUCGGCCGGCUUCUUGCUU-3′ (reverse);RXRα_siRNA, 5′-GGGAGAAGGUCUAUGCG
UCUU-3′ (forward) and 5′-GACGCAUAGACCUUCUCCCUU-3′ (reverse); and YY1_siRNA, 5′-
GGAUAACUCGGCCAUGAGAUU-3′ (forward) and 5′-UCUCAUGGCCGAGUUAUCCUU-
3′ (reverse). The cells were transfected using lipofectamine 2000 (Invitrogen, Waltham, MA,
USA) for plasmid DNA transfection and lipofectamine RNAiMAX (Invitrogen, Waltham,
MA, USA) for siRNA infection following the manufacturer’s protocol. AGS, MKN-28, SNU-
601 and SNU-668 cells were transfected with 2 µg of plasmid DNA at a 60 mm cell culture
dish. Moreover, AGS and MKN-28 cells were transfected with 20 µM of LAMB1_siRNA#1,
#2 or 30 µM siRNA (c-Jun, C/EBPβ, RXRα, and YY1) at a 60 mm cell culture dish. The
transfected cells were incubated for 48 h in a 37 ◦C incubator supplied with 5% atmospheric
CO2.
4.3. Total RNA Isolation and Reverse Transcriptase–Polymerase Chain Reaction (RT–PCR)
Total RNA was isolated using RNAiso Plus reagent (TaKaRa Bio, Kusatsu, Japan),
and cDNA was synthesized using cDNA Master Mix (ToYoBo, Ōsaka, Japan), accord-
ing to the manufacturer’s instructions. Then, PCR was performed by using HiPi Plus
5 × PCR Master Mix (Elpis Biotech, Daejeon, Korea). The primer sequences used in this
study were as follows: LAMB1, 5′-AGGTTGGAGCTGCCTCAGTA-3′ (forward) and 5′-
ACACTCCCTGGAAACAGTGG-3′ (reverse); JUN, 5′-CCCCAAGATCCTGAAACAGA-3′
(forward) and 5′-CCGTTGCTGGACTGGATTAT-3′ (reverse); CEBPB, 5′-CAAGAAGCCGG
CCGAGTAC-3′ (forward) and 5′-TTGTCCACGGTCTTCTTGGC-3′ (reverse); RXRA, 5′-
CCTTTCTCGGTCATCAGCTC-3′ (forward) and 5′-TGTCAATCAGGCAGTCCTTG-3′ (re-
verse); YY1, 5′-GGATAACTCGGCCATGAGAA-3′ (forward) and 5′-GGTTGTTTTTGGCCT
TAGCA-3′ (reverse); GAPDH, 5′-TGCACCACCAACTGCTTAG-3′ (forward) and 5′-GGATG
CAGGGATGATGTTC-3′ (reverse). PCR products were separated using 1% agarose gel
electrophoresis and visualized using RedSafe nucleic acid staining solution (iNtRON
Biotechnology, seongnam, Korea).
4.4. Protein Preparation and Western Blotting
The cells were lysed to extract the proteins using RIPA buffer. After incubation at
4 ◦C for 35 min, each sample was centrifuged at 13,200 rpm at 4 ◦C for 25 min. The
supernatant contained the protein. Protein concentration was measured using the bovine
serum albumin (BSA) protein assay (Thermo Fisher Scientific, Waltham, MA, USA). A
defined quantity of total protein was electrophoresed using 10–8% SDS–PAGE gels, and
the resolved protein bands were transferred to PVDF membranes. Each membrane was
blocked using 5% skimmed milk prepared in 0.05% Tween-20 with 1 × PBS (PBST) for
1 h 30 min at RT. After the reaction of blocking, each membrane was incubated at 4 ◦C
overnight with primary antibody diluted (1:1000) in 5% BSA prepared in PBST buffer. Each
membrane was incubated with diluted (1:5000) secondary antibody for 1 h 30 min at RT.
The bands were visualized through chemiluminescence (Bio-Rad, Seoul, Korea).
4.5. Antibodies
The monoclonal antibodies used were anti-laminin β-1, anti-ERK, anti-p-ERK, and
anti-β-actin (Santa Cruz Biotechnology), and the polyclonal antibodies used were anti-c-Jun
(Santa Cruz Biotechnology) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
Bioworld Technology, St Louis Park, MN, USA).
4.6. Colony-Formation Assay
Transfected cells were plated in a 35 mm culture dish (1500 cells). During incubation,
the medium was changed after every 3 days. After 10 days of incubation, colonies were
washed with cold 1 × PBS and fixed with 1% glutaraldehyde for 10 min. Colonies were
stained with 0.5% crystal violet for 10 min. Thereafter, the colonies formed in each dish
were counted. Each experiment was performed in triplicates.
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4.7. Invasion and Migration Assay
Transfected cells were plated in FBS-free medium at 2× 104 cells in the upper chamber
of a Transwell (Corning Costar) on a filter coated with 0.5 mg/mL collagen type I (BD
Biosciences, Franklin Lakes, NJ, USA) to perform the migration assay, and 1:15 diluted
Matrigel (BD Biosciences) coated filter to perform the invasion assay. RPMI 1640 medium
with 10% FBS and 1% antibiotics was added 1 mL to the lower chamber, followed by
incubation for 20 h in a 37 ◦C incubator supplied with 5% atmospheric CO2. Cell invasion
and migration were visualized and quantified by H&E staining. For quantification, cells
were counted from three randomly selected areas using wide-filed microscopy.
4.8. Cell Cycle Analysis
Transfected cells were incubated for 48 h at 37 ◦C. After incubation, cells were washed
with 1 × PBS and fixed in 5 mL of 75% ethanol at −20 ◦C overnight. After fixation, cells
were washed twice with cold 1 × PBS and dispersed in a staining solution containing
50 µg/mL RNase A and 50 µg/mL PI solution in PBS for 15 min at RT. Cell cycle distribution
was assessed after PI staining using the CytoFLEX flow cytometer (Beckman Coulter, Brea,
CA, USA).
4.9. Chromatin Immunoprecipitation (ChIP) Assay
AGS and MKN-28 cells of gastric cancer were cultured in a 150 mm culture dish
(2 × 105 cells). After 2 days of incubation, medium containing cells were treated with 1%
formaldehyde for cross-linking. ChIP assay was performed using the Pierse Agarose ChIP
Kit (Thermo Fisher Scientific), according to the manufacturer’s instructions. Anti-c-Jun and
normal rabbit lgG were used to immunoprecipitate DNA-containing complexes. Anti-c-
Jun was the same that antibody used in Western blotting. Anti-rabbit lgG was contained
in the ChIP kit and used as a negative control. Primers were designed with LAMB1
promoter binding sites: Primer 1, 5′-CTTCTCTGGGCCTTATTTCG-3′ (forward) and 5′-
CTGCTACCCTTAGCAATGGA-3′ (reverse), which was amplified region of 204-bp; primer 2,
5′-GGAGAATCGTCGAGATGAGC-3′ (forward) and 5′-CTGGGCAACAAGAGCAAAAC-
3′ (reverse), which was amplified region of 213-bp. Moreover, PCR was performed by
using HiPi Plus 5 × PCR Master Mix (Elpis Biotech, Daejeon, Korea).
4.10. Data Accession and Analysis
The data generated in this publication have been deposited to NCBI’s Gene Expres-
sion Omnibus (https://www.ncbi.nlm.nih.gov/geo) with GEO series accession numbers
GSE2685, GSE13861, GSE33651, and GSE63089. These data were normalized using GEO2R.
Genes with logFC > 0.7 were considered as differentially expressed genes (DEGs). As most
data values were log2-transformed in advance, we reprocessed the data accordingly. The
distribution of overexpressed genes in gastric cancer tissue is shown. Moreover, we confirm
the overall upregulated gene expression locus in public datasets. The gene expression
in normal tissues was calculated as one (relative expression > 1 means overexpression in
gastric cancer tissues).
4.11. Statistical Analysis
Data analyses were performed using GraphPad Prism5 software (GraphPad, San
Diego, CA, USA). Statistical analyses were performed using Student’s t-test. Overall,
survival, first progression, and post-progression survival of gastric cancer patients were
analyzed using Kaplan–Meier analysis (https://kmplot.com/analysis) and the data were
generated using the gene symbol LAMB1 (Affy ID: 201505_at and 211651_s_at). Gene on-
tology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analyses were performed using the Database for Annotation, Visualization and Integrated
Discovery (DAVID; david.ncifcrf.gov). p-value < 0.05 was considered to be statistically
significant. Moreover, all data presented as mean ± SEM.
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5. Conclusions
Our results revealed that LAMB1 is significantly overexpressed in gastric cancer
tissues and exerts the biological function of promoting tumor growth and cell invasion
and migration of gastric cancer cells. In this study, we showed that ERK/c-Jun regulates
LAMB1 expression and that LAMB1 is a potential therapeutic target for developing the
treatment of gastric cancer.
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